Global Ganja Report

Canada's postal unions are contemplating a nationwide walk-out—exactly as legal mail-order cannabis deliveries are set to begin. Talks are ongoing, but if the strike is not averted, cannabis consumers could be left high and dry—especially in those provinces that are relying mostly or entirely on home deliveries.

A major player in Canada's legal cannabis sector is seeking to acquire a troubled US-based company—the latest example of the trend toward consolidation in the industry now crossing international borders.

Justin Cooper is co-founder and CEO of British Columbia-based Green Planet, which supplies equipment to all of Canada's Licensed Producers of cannabis as well as producing its own line of fertilizers. He speaks with Cannabis Now about the fast-growing legal industry in his country, and what it means for the world.

As legal cannabis finally becomes a reality in Canada, a policy patchwork across the country's provinces and ongoing political tussles have left many confused as to what the new system will actually look like. We break down some of the frequently asked questions. 

A growing number among Canada's First Nations are looking to legal cannabis as a path to economic empowerment. Others are deeply skeptical, recalling the bitter history of substance abuse among Canada's indigenous communities. Yet all seem united in demanding sovereign control on the cannabis question within their own reserves.

Over the past two years, the Latin American cannabis industry has "emerged from the shadows" to command the attention of international firms and investors. Legal cannabis sales within the region are on track to reach $125 million in 2018—but that figure is expected to rise to $12.7 billion by 2028.

A legal medical marijuana export industry is coming to Jamaica, which has just dispatched its first shipment of cannabis oil to Canada. Long famous for its contraband product, the island nation now has a Cannabis Licensing Authority to oversee legal cultivation.

With the DEA's rescheduling of Epidiolex, shares in the British manufacturer of the drug are soaring. But CBD—the actual cannabinoid that the product is based on—is to remain in the restrictive Scheudle 1.